您的位置: 首页 > 农业专利 > 详情页

UTILISATION DE LAQUINIMOD POUR LE TRAITEMENT DE PATIENTS SOUFFRANT DE LA MALADIE DE CROHN POUR LESQUELS LA THERAPIE ANTI-TNF? DE PREMIERE INTENTION A ECHOUE
专利权人:
TEVA PHARMACEUTICAL INDUSTRIES LTD.
发明人:
TARCIC, NORA,HAVIV, ASI,BLAUGRUND, ERAN,KAYE, JOEL
申请号:
CA2862865
公开号:
CA2862865A1
申请日:
2013.02.01
申请国别(地区):
CA
年份:
2013
代理人:
摘要:
This application provides for a method of treating a human patient afflicted with anti-TNFa refractory Crohn's disease, of treating a human patient afflicted with non-fibrostenotic Crohn's disease, and of treating a human patient whose Crohn's disease had not been surgically treated, the method comprising periodically administering to the patient an amount of laquinimod or pharmaceutically acceptable salt thereof effective to treat the patient. This application also provides for a method of inducing or maintaining clinical remission in a human patient afflicted with Crohn's disease comprising periodically administering to the patient an amount of laquinimod effective to induce or maintain clinical remission in the patient, which amount of laquinimod is less than 0.5 mg/day.
来源网站:
中国工程科技知识中心
来源网址:
http://www.ckcest.cn/home/

意 见 箱

匿名:登录

个人用户登录

找回密码

第三方账号登录

忘记密码

个人用户注册

必须为有效邮箱
6~16位数字与字母组合
6~16位数字与字母组合
请输入正确的手机号码

信息补充